ea0070aep462 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020
luiza luca Bogdana
, Miguel Sierra Poyatos Roberto
, Cardenas Jersy
, Sanchez Gomez Nancy
, Jesus Silva Rodriguez Maria
, Modroño Mostoles Naiara
, Montoya Alvarez Teresa
, Sanchez Lopez Raquel
, Cruces Vega Eva
, Estrella Alicia
, Barrio Pilar
, Sanchez Lechuga Begoña
, Gonzalo Montesinos Irene
, Jose De la Cruz Fernandez Maria
, Perez Alvarez Enrique
, Vazquez Martinez Clotilde
Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...